Valbiotis Announces Capital Increase of €6.9 Million

Valbiotis SA has initiated a capital increase maintaining preferential subscription rights. The gross amount is nearly €6.9 million, supported by 75% subscription commitments. The subscription price is €0.88 per share, marking a 25.2% discount from the previous closing price. Existing shareholders will have the opportunity to subscribe at a parity of 1 new share for every 2 existing shares.

The raised funds will largely support commercial expansion, focusing on marketing and developing sales in France and internationally. Valbiotis aims to meet its financial goals, including reaching €25 million in sales by 2027, with aspirations for €100 million by 2030.

Valbiotis, focused on clinically tested dietary supplements, is embracing a multi-channel marketing strategy. With three products launched in France, the capital increase is intended to fuel continued growth and strength in the health supplement market.